Important Update for Pacira BioSciences Shareholders
The Gross Law Firm has issued a significant notice for the shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). If you purchased shares during the specified class period, you are encouraged to get in touch with the firm to discuss your options regarding a possible lead plaintiff appointment. Keep in mind that being appointed as a lead plaintiff is not a requirement to participate in any potential recovery.
Understanding the Class Period and Allegations
Investors should note the class period spans from August 2, 2023, to August 8, 2024. During this time, significant events unfolded leading to serious implications for shareholders.
The allegations stem from a complaint filed following a press release by Pacira on August 9, 2024. This release disclosed the results of a patent infringement lawsuit against eVenus, revealing that the court deemed Pacira's U.S. Patent No. 11,033,495 invalid. This ruling was critical as it impacted Pacira's main product, Exparel, which comprises about 80% of the company’s revenue.
Impact of the Court’s Ruling
The invalidation of the '495 patent has raised concerns regarding the strength of Pacira's other patents. Industry analysts have expressed that this development could lead to a surge in generic competitors entering the market, along with escalating litigation costs in the future. Consequently, Pacira's share price suffered a drastic downturn, plummeting over 47% in a single day—from $22.36 to $11.70.
Key Deadlines for Shareholders
The deadline for shareholders to act regarding this class action is set for March 14, 2025. It is essential for shareholders to register promptly to ensure they are included in the lawsuit.
Steps for Participation
Those registered as shareholders of PCRX during the class period will gain access to portfolio monitoring software. This tool will keep you updated about the ongoing status of the case, as well as any important legal developments. Remember, there are no costs or obligations involved in joining this legal action.
Why Choose The Gross Law Firm?
The Gross Law Firm is a renowned class-action law office dedicated to safeguarding the rights of investors impacted by deceitful practices. They advocate for responsible corporate behavior, aiming to secure recoveries for investors misled by false or incomplete information, which artificially inflated stock prices. The firm understands the complexities of corporate litigation and strives tirelessly to represent the interests of those affected.
Firm Contact Information
For inquiries, interested shareholders can reach out to The Gross Law Firm. They are located at:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the class period mentioned for PDTX?
The class period for Pacira BioSciences extends from August 2, 2023, through August 8, 2024.
What is the main allegation against Pacira BioSciences?
Pacira is facing allegations due to a court ruling that invalidated its key patent related to its primary product, Exparel.
When is the deadline to register for the class action?
The deadline to register for the class action is March 14, 2025.
How will I be updated about the case progress?
Once registered, shareholders will receive updates through a portfolio monitoring software provided by the law firm.
Is there a cost to participate in the class action?
No, there is no cost or obligation for shareholders to participate in this class action.
